Should frontline Hodgkin lymphoma therapy differ based on validated genetic, immunologic, or biochemical biomarkers?. // Blood Immunology & Cellular Therapy. – URL: https://www.sciencedirect.com/science/article/pii/S3050597626000618?dgcid=rss_sd_all
Should frontline Hodgkin lymphoma therapy differ based on validated genetic, immunologic, or biochemical biomarkers?. Blood Immunology & Cellular Therapy. https://www.sciencedirect.com/science/article/pii/S3050597626000618?dgcid=rss_sd_all
“Should frontline Hodgkin lymphoma therapy differ based on validated genetic, immunologic, or biochemical biomarkers?.” Blood Immunology & Cellular Therapy.
@article{article38184,
title = {Should frontline Hodgkin lymphoma therapy differ based on validated genetic, immunologic, or biochemical biomarkers?},
journal = {Blood Immunology \& Cellular Therapy},
url = {https://www.sciencedirect.com/science/article/pii/S3050597626000618?dgcid=rss_sd_all}
}
Publication date: November–December 2026 Source: Acta Otorrinolaringologica (English Edition), Volume 77, Issue 6 Author(s): Daniel Álvarez de Castro, Sandra Pérez de la Iglesia, Miguel Ramírez Verdyguer, Francisco José Manzano Gómez